Stocks · News reference
Guggenheim analyst Michael Schmitz maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $240 to $275.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Revolution Medicines, Inc. (NASDAQ:RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that
Revolution Medicines announced publication of Phase 1/2 clinical trial data for RASONQUE (daraxonrasib) in previously treated RAS mutant non-small cell lung cancer in the New England Journal of Medicine. The trial showed a 42% objective response rate and 16.0 months median overall survival in a docetaxel-naïve subgroup, with a manageable safety profile. Results support the ongoing Phase 3 RASolve 301 trial.
Bernie Sanders blasts Big Pharma over $400,000 cancer drugs, warning soaring treatment costs can push patients into financial ruin.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BMO Capital cut the price